pharma · Amyotrophic Lateral Sclerosis · Pharmacokinetics · NRSN
NeuroSense Therapeutics
NeuroSense Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker NRSN. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis, Pharmacokinetics, ALS (Amyotro
Cambridge, USA HQ
2017 Founded
30 Employees
Public company Type
NRSN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 30
- Programs
- 6
- Drugs
- 6
- Patents
- 2
Fixed dose combination Ciprofloxacin/Celecoxib
Phase 1 · small molecule · ALS (Amyotrophic Lateral Sclerosis)
Fixed dose combination Ciprofloxacin/Celecoxib for ALS (Amyotrophic Lateral Sclerosis) is a Phase 1 program (small_molecule) at NeuroSense Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code NST001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NeuroSense Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- ALS (Amyotrophic Lateral Sclerosis)
- Status
- completed
- Trials
- 1